Mot du directeur

The EA(UR) 7453 CHELTER brings together researchers in Hematology, Cytogenetics and Immunology, with the overall aim of better understanding the role of molecular, genetic or epigenetic abnormalities (methylation, telomere dynamics, metabolome, genetic mutations) in the therapeutic trajectories of patients with chronic hematological diseases, in particular chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). While these hemopathies now benefit from highly effective targeted therapies, therapeutic response remains heterogeneous, and personalized management is a major challenge.

The team's work is currently structured around 3 complementary themes, each of which is currently focused on the following areas:

1) Study of the relationship between individual frailty and biological aging, and their interest in predicting the tolerance and efficacy of targeted therapies, using the model of CML, a haemopathy that has pioneered the use of these innovative therapies. 

2) Study the mechanisms of resistance of CLL to targeted therapies and the molecular mechanisms of CLL transformation into Richter's lymphoma.

3) Development of original tools for immunotherapy, in particular CAR-T cells, and evaluation of the contribution of cell therapy (for the treatment of T lymphomas, hematological diseases with a poor prognosis).

Recent advances and ongoing projects are evidence of a real dynamic and fruitful collaboration. I would like to thank all the members of EA 7453 CHELTER for their involvement and the positive energy they bring to our projects.